Cyren (CYRNQ) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Document Information Line Items
Entity Registrant Name	CYREN Ltd.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		75,406,804
Amendment Flag	false
Entity Central Index Key	0001084577
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-26495
Entity Incorporation, State or Country Code	L3
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 16,455	$ 9,296
Trade receivables (net of allowances of $67 and $201, respectively)	721	960
Deferred commissions	953	980
Prepaid expenses and other receivables	820	779
Total current assets	18,949	12,015
LONG-TERM ASSETS:
Long-term deferred commissions	1,036	1,125
Long-term lease deposits and prepaids	861	937
Operating lease right-of-use assets	10,275	10,900
Severance pay fund	767	745
Property and equipment, net	3,360	3,948
Intangible assets, net	7,153	7,797
Goodwill	20,860	21,476
Total long-term assets	44,312	46,928
Total assets	63,261	58,943
CURRENT LIABILITIES:
Trade payables	882	799
Convertible notes (related party)	10,000	10,000
Employees and payroll accruals	3,811	3,813
Accrued expenses and other liabilities ($175 and $37 attributable to related parties, respectively)	1,236	1,420
Operating lease liabilities	1,863	1,983
Deferred revenues	4,106	6,934
Total current liabilities	21,898	24,949
LONG-TERM LIABILITIES:
Deferred revenues	583	644
Convertible Debentures ($235 and $234 attributable to related parties, respectively)	8,456	9,248
Long-term operating lease liabilities	9,107	9,866
Deferred tax liability	513	655
Accrued severance pay	839	838
Other liabilities	521	706
Total long-term liabilities	20,019	21,957
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Authorized: 110,000,000 shares as of March 31, 2021 (Unaudited) and December 31, 2020; Issued and Outstanding: 75,406,804 and 61,271,910 shares as of March 31, 2021 (Unaudited) and December 31, 2020, respectively	2,644	2,392
Additional paid-in capital	272,873	258,962
Accumulated other comprehensive loss	(1,384)	(725)
Accumulated deficit	(252,789)	(248,592)
Total shareholders’ equity	21,344	12,037
Total liabilities and shareholders’ equity	$ 63,261	$ 58,943

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) $ in Thousands	Mar. 31, 2021USD ($)shares	Mar. 31, 2021₪ / shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2020₪ / shares
Statement of Financial Position [Abstract]
Allowances for doubtful accounts | $	$ 67		$ 201
Accrued expenses and other liabilities attributable to related parties | $	175		37
Convertible debentures attributable to related parties | $	$ 235		$ 234
Ordinary shares, par value | ₪ / shares		₪ 0.15		₪ 0.15
Ordinary shares, authorized | shares	110,000,000		110,000,000
Ordinary shares, issued | shares	75,406,804		61,271,910
Ordinary shares, outstanding | shares	75,406,804		61,271,910

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenues	$ 8,757	$ 9,649
Cost of revenues	3,795	3,598
Gross profit	4,962	6,051
Operating expenses:
Research and development, net	4,250	3,344
Sales and marketing	2,638	3,036
General and administrative	2,160	2,214
Total operating expenses	9,048	8,594
Operating loss	(4,086)	(2,543)
Other income (expense), net	(18)	6
Financial expenses, net ($140 and $139 interest expense attributable to related parties, respectively)	(214)	(231)
Loss before taxes on income	(4,318)	(2,768)
Tax benefit	121	17
Net loss	$ (4,197)	$ (2,751)
Basic and diluted net loss per share (in Dollars per share)	$ (0.06)	$ (0.05)
Weighted-average number of shares used in computing basic net loss per share (in Shares)	68,469	59,684
Weighted-average numbers of shares used in computing diluted net loss per share (in Shares)	68,469	59,684

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Financial expenses, net attributable to related parties	$ 140	$ 139

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (4,197)	$ (2,751)
Other comprehensive loss:
Foreign currency translation adjustments	(659)	(288)
Comprehensive loss	$ (4,856)	$ (3,039)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($) $ in Thousands	Ordinary shares	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Total
Balance at Dec. 31, 2019	$ 2,309	$ 255,741	$ (2,010)	$ (231,329)	$ 24,711
Balance (in Shares) at Dec. 31, 2019	59,372,173
Restricted stock units vested	$ 26	(26)
Restricted stock units vested (in Shares)	593,632
Stock-based compensation related to employees, directors and consultants		645			645
Other comprehensive loss			(288)		(288)
Net loss				(2,751)	(2,751)
Balance at Mar. 31, 2020	$ 2,335	256,360	(2,298)	(234,080)	22,317
Balance (in Shares) at Mar. 31, 2020	59,965,805
Balance at Dec. 31, 2020	$ 2,392	258,962	(725)	(248,592)	12,037
Balance (in Shares) at Dec. 31, 2020	61,271,910
Stock issuance for financing, net of costs	$ 556	12,032			12,588
Stock issuance for financing, net of costs (in Shares)	12,000,000
Restricted stock units vested	$ 30	(30)
Restricted stock units vested (in Shares)	642,000
Placement agent warrants	$ (402)	402
Payment of interest in shares	$ 13	246			259
Payment of interest in shares (in Shares)	291,422
Stock-based compensation related to employees, directors and consultants		457			457
Issuance of shares upon early conversion of a Convertible Debentures	$ 55	804			859
Issuance of shares upon early conversion of a Convertible Debentures (in Shares)	1,201,472
Other comprehensive loss			(659)		(659)
Net loss				(4,197)	(4,197)
Balance at Mar. 31, 2021	$ 2,644	$ 272,873	$ (1,384)	$ (252,789)	$ 21,344
Balance (in Shares) at Mar. 31, 2021	75,406,804

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (4,197)	$ (2,751)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss on disposal of property and equipment	18	(13)
Depreciation	563	618
Stock-based compensation	457	645
Amortization of intangible assets	742	560
Amortization of deferred commissions	325	350
Non-cash operating lease expense	466	389
Interest on convertible notes	142	141
Interest and amortization of debt issuance costs on Convertible Debentures	176	24
Deferred taxes, net	(124)	(64)
Changes in assets and liabilities:
Trade receivables	211	(652)
Prepaid expenses and other receivables	2	(326)
Deferred commissions	(208)	(388)
Change in long-term lease deposits	2	(114)
Trade payables	62	45
Employees and payroll accruals, accrued expenses and other liabilities	(176)	(491)
Deferred revenues	(2,774)	(2,073)
Accrued severance pay, net	(21)	(23)
Operating lease liabilities	(731)	(420)
Other long-term liabilities	(186)	153
Net cash used in operating activities	(5,251)	(4,390)
Cash flows from investing activities:
Proceeds from sale of property and equipment	2	2
Capitalization of technology	(152)	(1,001)
Purchase of property and equipment	(18)	(558)
Net cash used in investing activities	(168)	(1,557)
Cash flows from financing activities:
Proceeds from Convertible Debentures, net of debt issuance costs		9,442
Proceeds from stock issuance, net of costs	12,588
Net cash provided by (used in) financing activities	12,588	9,442
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(30)	(6)
Increase (Decrease) in cash, cash equivalents and restricted cash	7,139	3,489
Cash, cash equivalents and restricted cash at the beginning of the period	9,914	12,127
Cash, cash equivalents and restricted cash at the end of the period	17,053	15,616
Supplemental disclosure of non-cash transactions:
Purchase of property and equipment by credit	(22)	(823)
Operating lease right-of-use asset exchanged for lease obligations		3,537
Issuance of shares on early conversion of Convertible Debentures	859
Issuance of shares for payment of interest on Convertible Debentures	259
Net change in accrued payroll expenses related to capitalization of technology	(10)	(243)
Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow:
Cash and cash equivalents	16,455	15,061
Restricted cash included in long-term restricted lease deposits	598	555
Total cash, cash equivalents and restricted cash	$ 17,053	$ 15,616

General

General	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
GENERAL	NOTE 1: GENERAL Cyren Ltd. (henceforth “Cyren”) was incorporated under the laws of the State of Israel on February 10, 1991 and its legal form is a company limited by shares. Cyren listed its shares to the public on July 15, 1999 under the name Commtouch Software Ltd. and changed its legal name to Cyren Ltd. in January 2014. Cyren and its subsidiaries, unless otherwise indicated will be referred to in these consolidated financial statements as the “Company”. The Company is engaged in developing and marketing cyber security solutions to identify and protect threats in email, files and from the web. The Company sells its cloud-based solutions worldwide, in both embedded and Software-as-a-Service models, to Original Equipment Manufacturers (“OEMs”), service providers and enterprises. The Company operates in one reportable segment, which constitutes its reporting unit.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2: SIGNIFICANT ACCOUNTING POLICIES a. Interim Financial Statements The accompanying consolidated balance sheet as of March 31, 2021, the consolidated statements of operations, the consolidated statements of comprehensive loss and the consolidated statements of cash flows for the three months ended March 31, 2021 and 2020, as well as the statement of changes in shareholders’ equity for the three months ended March 31, 2021, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of March 31, 2021, as well as its results of operations and cash flows for the three months ended March 31, 2021 and 2020. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for other interim periods or for future years. b. Over the past several years, the Company has devoted substantially most of its effort to research and product development, and increasing revenues through additional investments in sales & marketing. The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. At March 31, 2021, the Company’s cash and cash equivalents position is not sufficient to fund the Company’s planned operations for at least a year beyond the date of the filing date of the condensed consolidated financial statements. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand, reducing operating spend, divesting non-core assets and future issuances of equity and/or debt securities. On February 11, 2021, the Company entered into securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12,000,000 of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12,588. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The condensed consolidated financial statements for the three months ended March 31, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. c. Significant accounting policies The accompanying unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2021. Other than the change described below, there have been no changes to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that have had a material impact on the unaudited interim consolidated financial statements and related notes. d. Use of estimates: The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. e. Going Concern The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. U.S. GAAP requires an evaluation of whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued. Initially, this evaluation does not consider the potential mitigating effect of management’s plans that have not been fully implemented. When substantial doubt exists, management evaluates the mitigating effect of its plans if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued or prior to the conditions or events that create the going concern risk. The consolidated financial statements as of March 31, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. f. Recently issued and adopted pronouncements: In December 2019, the FASB issued ASU No. 2019-12, “Simplifying the Accounting for Income Taxes” under ASC 740, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. The Company adopted this new guidance in the first quarter of fiscal 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements. g. New accounting pronouncements not yet adopted: In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
LEASES	NOTE 3: LEASES The Company adopted the new standard as of January 1, 2019, using the modified retrospective approach. The modified retrospective approach provides a method for recording existing leases at adoption and in comparative periods that approximates the results of a full retrospective approach. The Company has elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard which does not require it to reassess the prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company has elected the short-term lease exception for leases with a term of 12 months or less. As part of this election it will not recognize right-of-use assets and lease liabilities on the balance sheet for Note 3 with terms less than 12 months. The Company also elected the practical expedient to not separate lease and non-lease components for all our leases. This will result in the initial and subsequent measurement of the balances of the right-of-use asset and lease liability being greater than if the policy election was not applied. Some leases include one or more options to extend the lease. The exercise of options to extend the lease is typically at the Company’s sole discretion; therefore, the majority of renewals to extend the lease terms are included in our right of use assets and lease liabilities as they are reasonably certain of exercise. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. Lease modifications result in remeasurement of the lease liability. The right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate based on the information available at the date of adoption in determining the present value of the lease payments. Some of the real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease adoption. Additional payments based on the change in an index or rate are recorded as a period expense when incurred. The Company has various operating leases for office space and vehicles that expire through 2030. Below is a summary of our operating right-of-use assets and operating lease liabilities as of March 31, 2021: Operating lease right-of-use assets $ 10,275 Operating lease liabilities, current $ 1,863 Operating lease liabilities long-term 9,107 Total operating lease liabilities $ 10,970 The short-term lease liabilities are included within accrued expenses and other short-term liabilities in the condensed consolidated balance sheet. Minimum lease payments for our right of use assets over the remaining lease periods as of March 31, 2021, are as follows: Year ended December 31, 2021 $ 1,792 2022 1,817 2023 1,615 2024 1,628 2025 1,641 Thereafter 4,478 Total undiscounted lease payments $ 12,971 Less: Interest 2,001 Present value of lease liabilities 10,970 Premises rent expense was $737 and $654 for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the Company subleases two real estate properties. Sublease receipts were $172 and $71 for the three months ended March 31, 2021 and 2020, respectively. The Company has elected the practical expedient to not separate lease components from non-lease components. The weighted-average remaining lease terms and discount rates for all of operating leases were as follows as of March 31, 2021: Remaining lease term and discount rate: Weighted-average remaining lease term (years) 7.0 Weighted-average discount rate 4.37 %

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 4: COMMITMENTS AND CONTINGENCIES a. Cyren Ltd., which was incorporated in Israel, partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (“IIA”) for the support of certain research and development activities conducted in Israel. In connection with specific research and development, the Company received $3,699 of participation payments from the IIA through March 31, 2021. In return for the IIA’s participation in this program, the Company is committed to pay royalties at a rate of 3% of the program’s developed product sales, up to 100% of the amount of grants received plus interest at annual LIBOR rate. The Company’s total commitment for royalties payable with respect to future sales, based on IIA participations received, net of royalties paid or accrued, totaled $2,656 and $2,714 as of March 31, 2021 and December 31, 2020 respectively. For the quarters ended March 31, 2021 and 2020, $22 and $69, respectively, were recorded as cost of revenues with respect to royalties due to the IIA. b. Litigation: i. On June 28, 2017 a vendor filed a Statement of Claim in the Tel Aviv District Court (the “SOC”). According to the vendor’s SOC, the Company entered into an agreement with the vendor for receipt of services, based on a database developed by the vendor. In September 2015, the Company terminated the agreement with the vendor, effective as of December 31, 2015. The vendor claimed that the Company had continued to make use of the vendor’s database post termination thus breaching the agreement, infringing on the vendor’s rights and commercial secrets, and being unjustly enriched. The vendor claimed damages of approximately $3,150 and injunctive relief ordering the Company and/or its customers to delete any remaining data and to cease from utilizing such data. The Company denied all claims and filed a Statement of Defense on November 15, 2017. Pretrial was scheduled for May 15, 2018. In accordance with the court’s recommendation from November 28, 2017, the parties agreed to examine a non-binding mediation process and appointed a mediator. The parties agreed to conduct a third-party audit of the Company’s databases in the scope of the mediation. In September 2018 and January 2019, the same vendor filed a lawsuit against two of the Company’s customers in the United States. The vendor alleged that the clients misappropriated the vendor’s trade secrets and sought injunctive relief and monetary damages in an amount to be determined. Both customers contended that the allegations related to the services they receive from the Company, and the Company agreed to indemnify both clients against these claims. On September 30, 2019, the court dismissed one of the lawsuits in its entirety for lack of personal jurisdiction and, in the second lawsuit, dismissed part of the claims with prejudice but granted the vendor the right to amend its other claims. On October 31, 2019, the vendor filed an amended complaint. In December 2019, the Company reached a settlement with the vendor and the Company agreed to pay $750; $375 in December 2019 and the remaining portion in January 2020. As of March 31, 2021, the Company has paid all amounts due under this settlement.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 5: ShareHOLDERS’ EQUITY a. General: Ordinary shares confer upon their holders the right to receive notice to participate and vote in general shareholder meetings of the Company and to receive dividends, if declared. b. Issuance of convertible notes: On December 5, 2018 the Company issued $10,000 aggregate principal amount of convertible notes in a private offering. The notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes have a 3-year term and are expected to mature in December 2021, unless converted in accordance with their terms prior to maturity. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted-average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. On November 7, 2019 Cyren announced the closing of a rights offering that raised gross proceeds of $8,019. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. In addition, the notes would be subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price). The Company incurred interest expense of $142 and $141 for the quarters ended March 31, 2021, and 2020, respectively. The Company has accrued interest of $174 as of March 31, 2021. The principal balance of the convertible notes as of March 31, 2021 was $10.0 million. c. Issuance of Convertible Debentures: In March 2020, the Company entered into purchase agreements with a select group of accredited investors for the purchase of $10.25 million aggregate principal amount of Convertible Debentures in a private placement. Upon the closing, the Company received approximately $9.4 million (net of $0.8 million in issuance expenses). The debentures are unsecured, subordinated obligations of Cyren and carry a 5.75% interest rate per annum, payable semi-annually in cash or ordinary shares at Cyren’s election. The debentures have a four-year term and mature in March 2024, unless converted in accordance with their terms prior to maturity. The debentures have a conversion price of $0.75 per share and are convertible into 1,333 ordinary shares per $1,000 principal amount of debentures. The conversion price is subject to adjustment based on the price and timing of future equity offerings and other customary adjustments. Upon the satisfaction of price and other conditions, Cyren has the right to force the conversion of the debentures. In March 2021, the Company paid semi-annual interest payments totaling, $259, which was paid through the issuance of 291,422 shares. For the quarter ended March 31, 2021, two debenture holders converted $909 of principal plus interest of their debentures, which was a portion of their holding. The principal and interest were paid through the issuance of 1,201,472 shares. The Company incurred interest expense of $176 for the quarter ended March 31, 2021, $49 of which is related to the amortization of debt issuance costs. The Company has accrued interest of $16 as of March 31, 2021 The principal balance of the Convertible Debentures as of March 31, 2021 was $9.0 million. As of March 31, 2021, the total estimated fair value of the Convertible Debentures was approximately $7.3 million. The fair value was determined based on the closing trading price of $0.81 per share multiplied by the Convertible Debentures principal balance as of the last day of trading for the period The fair value of the Convertible Debentures is considered a Level 2 within the fair value hierarchy and was determined based on inputs that are observable in the market or that could be derived from, or corroborated with, observable market data, quoted price of the Convertible Debentures in an over-the-counter market. d. Equity Incentive Plan: On December 22, 2016, the Company’s shareholders approved a new equity plan - the 2016 Equity Incentive Plan (the “Equity Incentive Plan”). This plan, along with its respective Israeli appendix, replaced all then-existing employee and consultants’ stock option plans. The Equity Incentive Plan allows for the issuance of Restricted Stock Units (“RSUs”), as well as options. The options and RSUs generally vest over a period of four years. Options granted under the Equity Incentive Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the optionee’s employment or other relationship with the Company. The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are cancelled or not exercised within the option term become available for future grant. On July 30, 2019, the shareholders of the Company approved an increase in the number of Ordinary Shares reserved for issuance under the 2016 Equity Incentive Plan and its respective Israeli Appendix to a total of 11,200,000. As of March 31, 2021, an aggregate of 6,191,972 ordinary shares of the Company are still available for future grant under the Equity Incentive Plan. e. Non-Employee Directors stock option plan: In 1999, the Company adopted the 1999 Directors Stock Option Plan, and in 2008 shareholders approved an extension of the term of this plan through July 13, 2019. On December 15, 2006, the plan was extended through 2016. On December 22, 2016, the Company’s shareholders approved a new equity plan - the 2016 Non-Employee Director Equity Incentive Plan (the “Non-Employee Director Plan”). This plan, along with its respective Israeli appendix, replaced all existing Directors stock option plans. The Non-Employee Director Plan allows for the issuance of Restricted Stock Units (“RSUs”), as well as options. Each option and RSU granted under the Non-Employee Plan generally vests over a period of four years. Each option has an exercise price equal to the fair market value of the ordinary shares on the grant date of such option. Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the relationship with the Company. On July 30, 2019 the shareholders of the Company approved an increase in the number of Ordinary Shares reserved for issuance under the Non-Employee Director Plan and its respective Israeli Appendix to a total of 1,150,000 Ordinary Shares. As of March 31, 2021, an aggregate of 830,550 ordinary shares of the Company are still available for future grant to non-employee directors. f. A summary of the Company’s employees and directors’ stock option activity under the plans is as follows: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2020 6,205,860 $ 2.09 3.18 $ - Granted 56,500 1.03 Exercised - - Expired and forfeited (1,075,527 ) 2.49 Outstanding at March 31, 2021 5,186,833 $ 2.00 3.26 $ - Options vested and expected to vest at March 31, 2021 5,062,104 $ 2.00 3.23 $ - Exercisable options at March 31, 2021 3,522,824 $ 2.03 2.79 $ - Weighted-average fair value of options granted during the quarter $ 0.53 The aggregate intrinsic value in the tables above represents the total intrinsic value (the difference between the fair value of the Company’s ordinary shares as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period. The total intrinsic value of options exercised during the quarters ended March 31, 2021 and 2020 was $0, and $0, respectively. The weighted-average grant date fair value of options granted to employees and directors during the quarters ended March 31, 2021, and 2020, was $0.53 and $0.48, respectively. As of March 31, 2021, the Company had $1,347 of unrecognized compensation expense related to non-vested stock options granted to employees and directors, expected to be recognized over a remaining weighted-average period of 2.00 years. g. The employee and directors’ options outstanding as of March 31, 2021, have been separated into ranges of exercise prices, as follows: Outstanding Exercisable Exercise Weighted- Weighted- Weighted- price per Options life in price per Options price per share outstanding years share exercisable share $0.85 - $1.64 1,502,373 3.49 $ 1.55 815,295 $ 1.53 $1.70 - $2.00 1,319,846 2.47 $ 1.88 1,187,900 $ 1.90 $2.05 - $2.14 1,167,316 3.94 $ 2.09 575,836 $ 2.09 $2.30 - $2.75 738,600 3.01 $ 2.39 550,927 $ 2.38 $2.90 - $3.20 458,698 3.41 $ 2.92 392,866 $ 2.92 5,186,833 3.26 $ 2.00 3,522,824 $ 2.03 h. Options to non-employees and non-directors: Issuance date Options outstanding Exercise price per share Options exercisable Exercisable through February 10, 2016 40,000 $ 1.44 40,000 Feb-22 January 24, 2017 25,000 $ 2.00 25,000 Jan-23 65,000 65,000 The options vest and become exercisable at a rate of 1/16 of the options every three months. As of March 31, 2021, the Company did not have any unrecognized compensation expense related to non-employee non-vested stock options. i. A summary of the Company’s RSUs activity for employees, directors and non-employees under the plans is as follows: Number of Weighted- Awarded and unvested at December 31, 2020 2,183,500 $ 1.50 Granted 3,719,500 0.91 Vested (642,000 ) 1.40 Forfeited (17,500 ) 2.30 Awarded and unvested at March 31, 2021 5,243,500 $ 1.09 As of March 31, 2021, the Company had approximately $5,433 of unrecognized compensation expense related to RSUs, expected to be recognized over a weighted-average period of 3.05 years. j. The total stock-based compensation expense related to all of the Company’s equity-based awards, recognized for the three-month periods ended March 31, 2021 and 2020 was as follows: Three months ended 2021 2020 Unaudited Cost of revenues $ 21 $ 44 Research and development 53 95 Sales and marketing 49 96 General and administrative 335 410 $ 458 $ 645

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	NOTE 6: SEGMENT AND GEOGRAPHIC INFORMATION Summary information about geographic areas: ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from licensing of software and sales of professional services, maintenance and technical support (see note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas: a. The following sets forth total revenue by solutions offered by geographic area based on the billing address of the customer: Three Months Ended 2021 2020 Unaudited United States $ 3,966 $ 4,434 Germany 2,125 2,097 Europe-Other 1,081 1,112 Asia Pacific 623 668 Israel 844 1,245 Other 118 93 $ 8,757 $ 9,649 b. Major customers: During the quarter ended March 31, 2021 and 2020, 23% and 22% of the Company’s revenues were derived from customer A. During the quarter ended March 31, 2021, no other customer accounted for more than 10% of total revenue. c. Remaining performance obligations: As of March 31, 2021, approximately $38,440 of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for non-cancellable contracts. The Company expects to recognize revenue on approximately 55% of these remaining performance obligations during the remainder of 2021, approximately 32% in 2022, with the remainder recognized thereafter. d. Revenue generated by Customer Type: March 31, March 31, 2021 2020 Unaudited Unaudited OEM/Embedded Security (*) $ 7,069 $ 7,906 Enterprise/SMB (**) 1,688 1,743 $ 8,757 $ 9,649 (*) This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Feeds into their infrastructure and/or products to protect their customers and users. (**) In this market, Cyren provides enterprise and SMB customers email security products and threat intelligence to help protect their employees, data and IP. e. The following sets forth the Company’s long-lived tangible assets by geographic area: March 31, December 31, 2021 2020 Unaudited Israel $ 6,202 $ 6,490 United States 1,607 1,964 Germany 4,736 5,247 Other 1,090 1,147 $ 13,635 $ 14,848

Financial Expense, Net

Financial Expense, Net	3 Months Ended
	Mar. 31, 2021
Other Income and Expenses [Abstract]
FINANCIAL EXPENSE, NET	NOTE 7: FINANCIAL EXPENSE, NET March 31, March 31 2021 2020 Unaudited Unaudited Income: Interest on cash and cash equivalents $ - $ - Expenses: Interest and accretion of discount (319 ) (163 ) Foreign currency exchange differences, net 121 (52 ) Other (16 ) (16 ) $ (214 ) $ (231 )

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 8: RELATED PARTIES a. Balances with related parties: March 31, December 31, 2021 2020 Unaudited Interest expense accrual – Convertible Notes (*) $ 174 $ 32 Interest expense accrual – Convertible Debentures (*) - 4 Short-term Convertible Notes (**) 10,000 10,000 Long-term Convertible Debentures (***) 235 234 (*) Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018 and the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See notes 5b. and 5c., respectively for further details. (**) Related to the Convertible Note entered into December 5, 2018. See note 5b. for further details. (***) Related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details. b. Transactions with related parties: March 31, March 31, 2021 2020 Unaudited Unaudited Interest expense on Convertible Notes (*) $ 142 $ 141 Interest expense on Convertible Debentures (**) $ 5 $ - (*) Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018. See note 5b. for further details. (**) Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 9: SUBSEQUENT EVENT On April 8, 2021, the Company received written notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market informing that because the closing bid price of the ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days prior to the date of the Notice the Company currently do not meet the minimum closing bid requirement for continued listing on the Nasdaq Capital Market set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules. The Company has until October 5, 2021 to regain compliance. If the Company does not regain compliance by October 5, 2021, the Company may be eligible for a second 180 day compliance period, provided that, on such date, the Company meets the continued listing requirement for market value of publicly held shares and all other applicable initial listing requirements for the Nasdaq Capital Market (other than the minimum closing bid price requirement) and the Company provides written notice to Nasdaq of its intention to cure the deficiency and plans for curing the deficiency during the second compliance period.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Interim Financial Statements	a. Interim Financial Statements The accompanying consolidated balance sheet as of March 31, 2021, the consolidated statements of operations, the consolidated statements of comprehensive loss and the consolidated statements of cash flows for the three months ended March 31, 2021 and 2020, as well as the statement of changes in shareholders’ equity for the three months ended March 31, 2021, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of March 31, 2021, as well as its results of operations and cash flows for the three months ended March 31, 2021 and 2020. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for other interim periods or for future years.
Research and product development	b. Over the past several years, the Company has devoted substantially most of its effort to research and product development, and increasing revenues through additional investments in sales & marketing. The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. At March 31, 2021, the Company’s cash and cash equivalents position is not sufficient to fund the Company’s planned operations for at least a year beyond the date of the filing date of the condensed consolidated financial statements. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through a combination of actions that may include existing cash on hand, reducing operating spend, divesting non-core assets and future issuances of equity and/or debt securities. On February 11, 2021, the Company entered into securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12,000,000 of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12,588. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The condensed consolidated financial statements for the three months ended March 31, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.
Significant accounting policies	c. Significant accounting policies The accompanying unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2021. Other than the change described below, there have been no changes to the significant accounting policies described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that have had a material impact on the unaudited interim consolidated financial statements and related notes
Use of estimates	d. Use of estimates: The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Going Concern	e. Going Concern The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. U.S. GAAP requires an evaluation of whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued. Initially, this evaluation does not consider the potential mitigating effect of management’s plans that have not been fully implemented. When substantial doubt exists, management evaluates the mitigating effect of its plans if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued or prior to the conditions or events that create the going concern risk. The consolidated financial statements as of March 31, 2021 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.
Recently issued and adopted pronouncements	f. Recently issued and adopted pronouncements: In December 2019, the FASB issued ASU No. 2019-12, “Simplifying the Accounting for Income Taxes” under ASC 740, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. The Company adopted this new guidance in the first quarter of fiscal 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements.
New accounting pronouncements not yet adopted	g. New accounting pronouncements not yet adopted: In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of operating right-of-use assets and operating lease liabilities	Operating lease right-of-use assets $ 10,275 Operating lease liabilities, current $ 1,863 Operating lease liabilities long-term 9,107 Total operating lease liabilities $ 10,970
Schedule of weighted average remaining lease terms and discount rates for all of operating leases	Year ended December 31, 2021 $ 1,792 2022 1,817 2023 1,615 2024 1,628 2025 1,641 Thereafter 4,478 Total undiscounted lease payments $ 12,971 Less: Interest 2,001 Present value of lease liabilities 10,970
Schedule of weighted average remaining lease terms and discount rates for all of operating leases	Remaining lease term and discount rate: Weighted-average remaining lease term (years) 7.0 Weighted-average discount rate 4.37 %

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of employees and directors' stock option activity	Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2020 6,205,860 $ 2.09 3.18 $ - Granted 56,500 1.03 Exercised - - Expired and forfeited (1,075,527 ) 2.49 Outstanding at March 31, 2021 5,186,833 $ 2.00 3.26 $ - Options vested and expected to vest at March 31, 2021 5,062,104 $ 2.00 3.23 $ - Exercisable options at March 31, 2021 3,522,824 $ 2.03 2.79 $ - Weighted-average fair value of options granted during the quarter $ 0.53
Schedule of employee and director options outstanding	Outstanding Exercisable Exercise Weighted- Weighted- Weighted- price per Options life in price per Options price per share outstanding years share exercisable share $0.85 - $1.64 1,502,373 3.49 $ 1.55 815,295 $ 1.53 $1.70 - $2.00 1,319,846 2.47 $ 1.88 1,187,900 $ 1.90 $2.05 - $2.14 1,167,316 3.94 $ 2.09 575,836 $ 2.09 $2.30 - $2.75 738,600 3.01 $ 2.39 550,927 $ 2.38 $2.90 - $3.20 458,698 3.41 $ 2.92 392,866 $ 2.92 5,186,833 3.26 $ 2.00 3,522,824 $ 2.03
Schedule of options to non-employees	Issuance date Options outstanding Exercise price per share Options exercisable Exercisable through February 10, 2016 40,000 $ 1.44 40,000 Feb-22 January 24, 2017 25,000 $ 2.00 25,000 Jan-23 65,000 65,000
Schedule of RSUs activity	Number of Weighted- Awarded and unvested at December 31, 2020 2,183,500 $ 1.50 Granted 3,719,500 0.91 Vested (642,000 ) 1.40 Forfeited (17,500 ) 2.30 Awarded and unvested at March 31, 2021 5,243,500 $ 1.09
Schedule of stock-based compensation expense	Three months ended 2021 2020 Unaudited Cost of revenues $ 21 $ 44 Research and development 53 95 Sales and marketing 49 96 General and administrative 335 410 $ 458 $ 645

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of total revenue by solutions offered by geographic area	Three Months Ended 2021 2020 Unaudited United States $ 3,966 $ 4,434 Germany 2,125 2,097 Europe-Other 1,081 1,112 Asia Pacific 623 668 Israel 844 1,245 Other 118 93 $ 8,757 $ 9,649
Schedule of revenue generated by Customer Type	March 31, March 31, 2021 2020 Unaudited Unaudited OEM/Embedded Security (*) $ 7,069 $ 7,906 Enterprise/SMB (**) 1,688 1,743 $ 8,757 $ 9,649 (*) This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Feeds into their infrastructure and/or products to protect their customers and users. (**) In this market, Cyren provides enterprise and SMB customers email security products and threat intelligence to help protect their employees, data and IP.
Schedule of net amount of property and equipment	March 31, December 31, 2021 2020 Unaudited Israel $ 6,202 $ 6,490 United States 1,607 1,964 Germany 4,736 5,247 Other 1,090 1,147 $ 13,635 $ 14,848

Financial Expense, Net (Tables)

Financial Expense, Net (Tables)	3 Months Ended
	Mar. 31, 2021
Other Income and Expenses [Abstract]
Schedule of financial expense, net	March 31, March 31 2021 2020 Unaudited Unaudited Income: Interest on cash and cash equivalents $ - $ - Expenses: Interest and accretion of discount (319 ) (163 ) Foreign currency exchange differences, net 121 (52 ) Other (16 ) (16 ) $ (214 ) $ (231 )

Related Parties (Tables)

Related Parties (Tables)	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Schedule of related party balances	March 31, December 31, 2021 2020 Unaudited Interest expense accrual – Convertible Notes (*) $ 174 $ 32 Interest expense accrual – Convertible Debentures (*) - 4 Short-term Convertible Notes (**) 10,000 10,000 Long-term Convertible Debentures (***) 235 234 (*) Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018 and the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See notes 5b. and 5c., respectively for further details. (**) Related to the Convertible Note entered into December 5, 2018. See note 5b. for further details. (***) Related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details.
Schedule of related party transactions	March 31, March 31, 2021 2020 Unaudited Unaudited Interest expense on Convertible Notes (*) $ 142 $ 141 Interest expense on Convertible Debentures (**) $ 5 $ - (*) Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018. See note 5b. for further details. (**) Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details.

Significant Accounting Polici_2

Significant Accounting Policies (Details)	Feb. 11, 2021
Accounting Policies [Abstract]
Securities purchase agreement, description	the Company entered into securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12,000,000 of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12,588.

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure Text Block [Abstract]
Premises rent expense	$ 737	$ 654
Sublease receipts	$ 172	$ 71

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating right-of-use assets and operating lease liabilities - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of operating right-of-use assets and operating lease liabilities [Abstract]
Operating lease right-of-use assets	$ 10,275	$ 10,900
Operating lease liabilities, current	1,863	1,983
Operating lease liabilities long-term	9,107	$ 9,866
Total operating lease liabilities	$ 10,970

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of future minimum lease payments $ in Thousands	Mar. 31, 2021USD ($)
Schedule of future minimum lease payments [Abstract]
2021	$ 1,792
2022	1,817
2023	1,615
2024	1,628
2025	1,641
Thereafter	4,478
Total undiscounted lease payments	12,971
Less: Interest	2,001
Present value of lease liabilities	$ 10,970

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of weighted average remaining lease terms and discount rates for all of operating leases	Mar. 31, 2021
Schedule of weighted average remaining lease terms and discount rates for all of operating leases [Abstract]
Weighted-average remaining lease term (years)	7 years
Weighted-average discount rate	4.37%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Company received grants from the IIA	$ 3,699
Settlement agreement, description	In return for the IIA’s participation in this program, the Company is committed to pay royalties at a rate of 3% of the program’s developed product sales, up to 100% of the amount of grants received plus interest at annual LIBOR rate.
Net of royalties paid or accrued	$ 2,656		$ 2,714
Royalties revenue	22	$ 69
Claims settlement amount	3,150
Settle of earn-out consideration	$ 750	$ 375

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	1 Months Ended			3 Months Ended
	Mar. 31, 2020	Nov. 07, 2019	Dec. 05, 2018	Mar. 31, 2021	Mar. 31, 2020	Jul. 30, 2019
Shareholders' Equity (Details) [Line Items]
Aggregate principal amount			$ 10,000,000
Debt instrument, description			The notes are unsecured, unsubordinated obligations of Cyren and carry a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes have a 3-year term and are expected to mature in December 2021, unless converted in accordance with their terms prior to maturity. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted-average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding.	For the quarter ended March 31, 2021, two debenture holders converted $909 of principal plus interest of their debentures, which was a portion of their holding.
Gross proceeds		$ 8,019,000		$ 12,588,000
Conversion price, per share (in Dollars per share)		$ 3.73
Interest expense				142,000	$ 141,000
Accrued interest				$ 174,000
Issuance expenses	$ 800,000
Principal and interest issuance of shares (in Shares)				1,201,472
Interest expenses				$ 176
Amortization of debt issuance costs				49
Accrued interest				16,000
Fair value of convertible debenture				$ 7,300
Closing price (in Dollars per share)				$ 0.81
Options grant/vest, description				The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are cancelled or not exercised within the option term become available for future grant.
Ordinary shares available for future grant (in Shares)				6,191,972		11,200,000
Intrinsic value of options exercised				$ 0	$ 0
Weighted average grant date value of option granted (in Dollars per share)				$ 0.53	$ 0.48
Unrecognized compensation expense				$ 1,347,000
Recognized over remaining weighted average period				2 years
Options grant/vest, description				The options vest and become exercisable at a rate of 1/16 of the options every three months.
Issuance of convertible notes [Member]
Shareholders' Equity (Details) [Line Items]
Aggregate principal amount				$ 10,000,000
Convertible Notes Payable [Member]
Shareholders' Equity (Details) [Line Items]
Aggregate principal amount	10,250,000			$ 1,000,000	$ 10,250,000
Interest rate				5.75%
Convertible Debentures [Member]
Shareholders' Equity (Details) [Line Items]
Aggregate principal amount	$ 9,400,000				$ 9,400,000
Conversion price, per share (in Dollars per share)				$ 0.75
Convertible shares (in Shares)				1,333
Issuance of Convertible Debentures [Member]
Shareholders' Equity (Details) [Line Items]
Aggregate principal amount				$ 9,000
Interest payments				$ 259,000
Issuance of shares (in Shares)				291,422
Restricted Stock Units (RSUs) [Member]
Shareholders' Equity (Details) [Line Items]
Weighted average grant date value of option granted (in Dollars per share)				$ 0.91
Unrecognized compensation expense				$ 5,433,000
Recognized over remaining weighted average period				3 years 18 days
Non-Employee Plan [Member]
Shareholders' Equity (Details) [Line Items]
Number of ordinary shares reserved for issuance (in Shares)						1,150,000
Ordinary shares available for future grant (in Shares)				830,550

Shareholders' Equity (Details)

Shareholders' Equity (Details) - Schedule of employees and directors' stock option activity - Employees and directors' stock option [Member]	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Shareholders' Equity (Details) - Schedule of employees and directors' stock option activity [Line Items]
Outstanding, Beginning balance (in Shares) | shares	6,205,860
Outstanding, Beginning balance	$ 2.09
Outstanding, Beginning balance	3 years 65 days
Outstanding, Ending balance (in Dollars) | $
Granted (in Shares) | shares	56,500
Granted	$ 1.03
Exercised (in Shares) | shares
Exercised
Expired and forfeited (in Shares) | shares	(1,075,527)
Expired and forfeited	$ 2.49
Outstanding, Ending balance (in Shares) | shares	5,186,833
Outstanding, Ending balance	$ 2
Outstanding, Ending balance	3 years 94 days
Outstanding, Ending balance (in Dollars) | $
Options vested and expected to vest (in Shares) | shares	5,062,104
Options vested and expected to vest	$ 2
Options vested and expected to vest	3 years 83 days
Options vested and expected to vest (in Dollars) | $
Exercisable options (in Shares) | shares	3,522,824
Exercisable options	$ 2.03
Exercisable options	2 years 288 days
Exercisable options (in Dollars) | $
Weighted average fair value of options granted during the quarter	$ 0.53

Shareholders' Equity (Details_2

Shareholders' Equity (Details) - Schedule of employee and director options outstanding	3 Months Ended
	Mar. 31, 2021$ / sharesshares
$0.85 - $1.64 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding | shares	1,502,373
Weighted average remaining contractual life in years	3 years 178 days
Weighted average exercise price per share, Option outstanding | $ / shares	$ 1.55
Options exercisable | shares	815,295
Weighted average exercise price per share, exercisable | $ / shares	$ 1.53
$1.70 - $2.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding | shares	1,319,846
Weighted average remaining contractual life in years	2 years 171 days
Weighted average exercise price per share, Option outstanding | $ / shares	$ 1.88
Options exercisable | shares	1,187,900
Weighted average exercise price per share, exercisable | $ / shares	$ 1.90
$2.05 - $2.14 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding | shares	1,167,316
Weighted average remaining contractual life in years	3 years 343 days
Weighted average exercise price per share, Option outstanding | $ / shares	$ 2.09
Options exercisable | shares	575,836
Weighted average exercise price per share, exercisable | $ / shares	$ 2.09
$2.30 - $2.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding | shares	738,600
Weighted average remaining contractual life in years	3 years 3 days
Weighted average exercise price per share, Option outstanding | $ / shares	$ 2.39
Options exercisable | shares	550,927
Weighted average exercise price per share, exercisable | $ / shares	$ 2.38
$2.90 - $3.20 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding | shares	458,698
Weighted average remaining contractual life in years	3 years 149 days
Weighted average exercise price per share, Option outstanding | $ / shares	$ 2.92
Options exercisable | shares	392,866
Weighted average exercise price per share, exercisable | $ / shares	$ 2.92
Exercise Price Range [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding | shares	5,186,833
Weighted average remaining contractual life in years	3 years 94 days
Weighted average exercise price per share, Option outstanding | $ / shares	$ 2
Options exercisable | shares	3,522,824
Weighted average exercise price per share, exercisable | $ / shares	$ 2.03

Shareholders' Equity (Details_3

Shareholders' Equity (Details) - Schedule of options to non-employees	3 Months Ended
	Mar. 31, 2021$ / sharesshares
February 10, 2016 [Member]
Shareholders' Equity (Details) - Schedule of options to non-employees [Line Items]
Options outstanding	40,000
Exercise price per share (in Dollars per share) | $ / shares	$ 1.44
Options exercisable	40,000
Exercisable through	Feb-22
January 24, 2017 [Member]
Shareholders' Equity (Details) - Schedule of options to non-employees [Line Items]
Options outstanding	25,000
Exercise price per share (in Dollars per share) | $ / shares	$ 2
Options exercisable	25,000
Exercisable through	Jan-23
Issuance date [Member]
Shareholders' Equity (Details) - Schedule of options to non-employees [Line Items]
Options outstanding	65,000
Options exercisable	65,000

Shareholders' Equity (Details_4

Shareholders' Equity (Details) - Schedule of RSUs activity - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Shareholders' Equity (Details) - Schedule of RSUs activity [Line Items]
Awarded and unvested | shares	2,183,500
Awarded and unvested | $ / shares	$ 1.50
Granted | shares	3,719,500
Granted | $ / shares	$ 0.91
Vested | shares	(642,000)
Vested | $ / shares	$ 1.40
Forfeited | shares	(17,500)
Forfeited | $ / shares	$ 2.30
Awarded and unvested | shares	5,243,500
Awarded and unvested | $ / shares	$ 1.09

Shareholders' Equity (Details_5

Shareholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 458	$ 645
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	21	44
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	53	95
Sales and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	49	96
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 335	$ 410

Segment and Geographic Inform_3

Segment and Geographic Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Segment Reporting [Abstract]
Segment reporting, major customer's description	During the quarter ended March 31, 2021 and 2020, 23% and 22% of the Company’s revenues were derived from customer A. During the quarter ended March 31, 2021, no other customer accounted for more than 10% of total revenue.
Revenue remaining performance obligation	$ 38,440
Description of revenue remaining performance obligation	The Company expects to recognize revenue on approximately 55% of these remaining performance obligations during the remainder of 2021, approximately 32% in 2022, with the remainder recognized thereafter.

Segment and Geographic Inform_4

Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	$ 8,757	$ 9,649
United States [Member]
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	3,966	4,434
Germany [Member]
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	2,125	2,097
Europe-Other [Member]
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	1,081	1,112
Asia Pacific [Member]
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	623	668
Israel [Member]
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	844	1,245
Other [Member]
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	$ 118	$ 93

Segment and Geographic Inform_5

Segment and Geographic Information (Details) - Schedule of revenue generated by customer type - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Revenue from External Customer [Line Items]
Revenues from external customers		$ 8,757	$ 9,649
OEM/Embedded Security [Member]
Revenue from External Customer [Line Items]
Revenues from external customers	[1]	7,069	7,906
Enterprise/SMB [Member]
Revenue from External Customer [Line Items]
Revenues from external customers	[2]	$ 1,688	$ 1,743
[1]	This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Feeds into their infrastructure and/or products to protect their customers and users.
[2]	In this market, Cyren provides enterprise and SMB customers email security products and threat intelligence to help protect their employees, data and IP.

Segment and Geographic Inform_6

Segment and Geographic Information (Details) - Schedule of net amount of property and equipment - USD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Segment and Geographic Information (Details) - Schedule of net amount of property and equipment [Line Items]
Net amount of property and equipment	$ 14,848	$ 13,635
Israel [Member]
Segment and Geographic Information (Details) - Schedule of net amount of property and equipment [Line Items]
Net amount of property and equipment	6,490	6,202
United States [Member]
Segment and Geographic Information (Details) - Schedule of net amount of property and equipment [Line Items]
Net amount of property and equipment	1,964	1,607
Germany [Member]
Segment and Geographic Information (Details) - Schedule of net amount of property and equipment [Line Items]
Net amount of property and equipment	5,247	4,736
Other [Member]
Segment and Geographic Information (Details) - Schedule of net amount of property and equipment [Line Items]
Net amount of property and equipment	$ 1,147	$ 1,090

Financial Expense, Net (Details

Financial Expense, Net (Details) - Schedule of financial expense, net - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income:
Interest on cash and cash equivalents
Expenses:
Interest and accretion of discount	(319)	(163)
Foreign currency exchange differences, net	121	(52)
Other	(16)	(16)
Total financial expenses	$ (214)	$ (231)

Related Parties (Details) - Sch

Related Parties (Details) - Schedule of related party balances - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Schedule of related party balances [Abstract]
Interest expense accrual – Convertible Notes	[1]	$ 174	$ 32
Interest expense accrual – Convertible Debentures	[1]		4
Short term Convertible Notes	[2]	10,000	10,000
Long term Convertible Debentures	[3]	$ 235	$ 234
[1]	Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018 and the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See notes 5b. and 5c., respectively for further details.
[2]	Related to the Convertible Note entered into December 5, 2018. See note 5b. for further details.
[3]	Related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details.

Related Parties (Details) - S_2

Related Parties (Details) - Schedule of related party transactions - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Schedule of related party transactions [Abstract]
Interest expense on Convertible Notes	[1]	$ 142	$ 141
Interest expense on Convertible Debentures	[2]	$ 5
[1]	Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018. See note 5b. for further details.
[2]	Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See note 5c. for further details.

Subsequent Event (Details)

Subsequent Event (Details)	Apr. 08, 2021
Subsequent Event [Member]
Subsequent Event (Details) [Line Items]
Written notice, description	Listing Qualifications Department of the Nasdaq Stock Market informing that because the closing bid price of the ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days prior to the date of the Notice the Company currently do not meet the minimum closing bid requirement for continued listing on the Nasdaq Capital Market set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.